Burn rate will skyrocket as all the additional US sites are activated. More studies probably will be required to explain patients who get worse in the severe group. Longevity of effect, DMOAD activity, side effects (seen in veterinary-see Cartrophen insert). Dose response not guaranteed by any stretch- what will they do then- start again? IMO DYOR
By the way no placebo data in dog study touted as research- what is the use of that- just more smoke. Vet investors need to reassess. IMO DYOR
Arthritis in dogs is different to OA in humans which takes 40-50 years to develop.
research reports and media, page-3547
-
- There are more pages in this discussion • 624 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |